A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Update Il y a 4 ans
Reference: EUCTR2007-001396-11

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the efficacy of PXD101 treatment as measured by objective response rate. Objective response (OR) is best overall response of CR or PR. CTCL response assessment is based on the severity-weighted assessment tool (SWAT) (Stevens 2002) with Cheson criteria applied in addition for determination of PD. PTCL response will be assessed using the criteria of Cheson et al. (Cheson 2007).


Inclusion criteria

  • T-cell Lymphoma